Bristol Myers Squibb Financial Ratios
BMY / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
38.2%
ROE ranks in the above average among Health Care companies
Profit Margin
14.6%
Net Income / Revenue
Asset Turnover
0.54
Revenue / Total Assets
Equity Multiplier
4.87
Total Assets / Equity
Composite: 38.2% (reported: 38.2%)
Profitability
Gross Margin
-
Operating Margin
-
EBITDA
$13.3B
EBITDA Margin
27.7%
Liquidity
Current Ratio
1.26
Quick Ratio
1.14
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.54
Inventory Turnover
5.18
Days Sales Outstanding
73 days
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Earnings Quality
Accrual Ratio
-7.8%
+18.3pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.